Premium
Eosinophilia associated with clozapine therapy
Author(s) -
Lam Y. W. Francis
Publication year - 2021
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30740
Subject(s) - leukopenia , clozapine , medicine , eosinophilia , neutropenia , eosinophil , limiting , white blood cell , schizophrenia (object oriented programming) , blood count , gastroenterology , chemotherapy , psychiatry , mechanical engineering , asthma , engineering
Clozapine is used in the management of treatment‐resistant schizophrenia. However, its utility is limited by the occurrence of agranulocytosis, neutropenia, and leukopenia in up to 3% of patients, necessitating regular monitoring of hematological laboratory indices. In addition, several cases of self‐limiting eosinophilia have been reported in the literature, with most cases occurring 4 weeks after treatment initiation and rarely exceeding a 35% relative eosinophil count (percentage of white blood cells that are eosinophils).